Skip to main content
SpringerLink
Log in

Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

A 79-year-old female patient with multiple myeloma who had no prior cardiac disease history developed an acute myocardial infarction on day 5 after receiving bortezomib and dexamethasone (BD). After treatment of coronary stenoses by stents, she received another course of BD therapy and developed angina pectoris on day 5 after the therapy. Bortezomib’s antitumor effect is due to the inhibition of proteasome activity. This inhibition may increase endothelial progenitor cell apoptosis and decrease endothelial nitric oxide synthase/nitric oxide (eNOS/NO), thus leading to coronary spasm. It is, therefore, important to carefully monitor patients being treated with bortezomib for the potential occurrence of ischemic heart disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Blade J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557–60.

    Article  CAS  PubMed  Google Scholar 

  2. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev. 2003;29(Suppl 1):33–9.

    Article  CAS  PubMed  Google Scholar 

  3. Suvannasankha A, Smith GG, Juliar BE, Abonour R. Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma. 2006;7:131–4.

    Article  CAS  PubMed  Google Scholar 

  4. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer. 2006;6:129.

    Article  PubMed  Google Scholar 

  5. Hacihanefioglu A, Tarkun P, Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol. 2008;88:219–22.

    Article  PubMed  Google Scholar 

  6. Orciuolo E, Buda G, Cecconi N, Galimberti S, Versari D, Cervetti G, Salvetti A, Petrini M. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol. 2007;138:396–7.

    Article  CAS  Google Scholar 

  7. Foley PW, Hamilton MS, Leyva F. Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance. J Cardiovasc Med (Hagerstown). 2010;11:386–8.

    Google Scholar 

  8. Wada M, Mizoguchi H, Kuriya SI, Taguchi H, Kawamura T, Maekawa I, Shimazaki C, Sato Y, Niho Y, Miyazaki T, Shibata A, Kitani T, Hamajima N, Ohno R. Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan. Br J Haematol. 2000;109:805–14.

    Article  CAS  PubMed  Google Scholar 

  9. Martino M, Console G, Callea V, Stelitano C, Massara E, Irrera G, Messina G, Morabito F, Iacopino P. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. Eur J Haematol. 2007;78:35–40.

    Article  CAS  PubMed  Google Scholar 

  10. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.

    Article  CAS  PubMed  Google Scholar 

  11. Jilma B, Cvitko T, Winter-Fabry A, Petroczi K, Quehenberger P, Blann AD. High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men. Thromb Haemost. 2005;94:797–801.

    PubMed  Google Scholar 

  12. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, Paul N, Clouse ME, Shapiro EP, Hoe J, Lardo AC, Bush DE, de Roos A, Cox C, Brinker J, Lima JA. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med. 2008;359:2324–36.

    Article  CAS  PubMed  Google Scholar 

  13. Miller JM, Dewey M, Vavere AL, Rochitte CE, Niinuma H, Arbab-Zadeh A, Paul N, Hoe J, de Roos A, Yoshioka K, Lemos PA, Bush DE, Lardo AC, Texter J, Brinker J, Cox C, Clouse ME, Lima JA. Coronary CT angiography using 64 detector rows: methods and design of the multi-centre trial CORE-64. Eur Radiol. 2009;19:816–28.

    Article  PubMed  Google Scholar 

  14. Nagao M, Matsuoka H, Kawakami H, Higashino H, Mochizuki T, Ohshita A, Kohno T, Shigemi S. Detection of myocardial ischemia using 64-slice MDCT. Circ J. 2009;73:905–11.

    Article  PubMed  Google Scholar 

  15. Hu XS, Du CQ, Yang L, Yao XY, Hu SJ. Proteasome inhibitor MG132 suppresses number and function of endothelial progenitor cells: involvement of nitric oxide synthase inhibition. Int J Mol Med. 2010;25:385–92.

    Article  CAS  PubMed  Google Scholar 

  16. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K. T-786– > C mutation in the 5’-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation. 1999;99:2864–70.

    CAS  PubMed  Google Scholar 

  17. Govers R, de Bree P, Rabelink TJ. Involvement of the proteasome in activation of endothelial nitric oxide synthase. Life Sci. 2003;73:2225–36.

    Article  CAS  PubMed  Google Scholar 

  18. Belloni D, Veschini L, Foglieni C, Dell’Antonio G, Caligaris-Cappio F, Ferrarini M, Ferrero E. Bortezomib induces autophagic death in proliferating human endothelial cells. Exp Cell Res. 2010;316:1010–8.

    Article  CAS  PubMed  Google Scholar 

  19. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P, Baumann G, Kloetzel PM, Stangl K. Ubiquitin–proteasome pathway as a new target for the prevention of restenosis. Circulation. 2002;105:483–9.

    Article  CAS  PubMed  Google Scholar 

  20. Martinet W, Kockx MM. Apoptosis in atherosclerosis: implications for plaque destabilization. Verh K Acad Geneeskd Belg. 2004;66:61–79.

    CAS  PubMed  Google Scholar 

  21. Kavurma MM, Bhindi R, Lowe HC, Chesterman C, Khachigian LM. Vessel wall apoptosis and atherosclerotic plaque instability. J Thromb Haemost. 2005;3:465–72.

    Article  CAS  PubMed  Google Scholar 

  22. Versari D, Herrmann J, Gossl M, Mannheim D, Sattler K, Meyer FB, Lerman LO, Lerman A. Dysregulation of the ubiquitin–proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2132–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Drs. Teruhiko Kumamoto and Naoto Tama of Kanazawa Cardiovascular Hospital, Hiroo Chikazawa of Yamanaka Onsen Medical Center and Ippei Sakamaki of National Hospital Organization Awara Hospital for excellent therapy to this patient and her clinical information. We would also like to express our gratitude to Dr. Shinichiro Takashima, Department of Cardiology of Kanazawa University for valuable suggestions and helpful discussions.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, NTT WEST Kanazawa Hospital, 6-26 Shimoshinmachi, Kanazawa, Ishikawa, 920-0910, Japan

    Hiroyuki Takamatsu, Takeshi Yamashita, Takeharu Kotani & Aiko Sawazaki

  2. Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan

    Hiroyuki Takamatsu, Hirokazu Okumura & Shinji Nakao

Authors
  1. Hiroyuki Takamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeharu Kotani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aiko Sawazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirokazu Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinji Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroyuki Takamatsu.

About this article

Cite this article

Takamatsu, H., Yamashita, T., Kotani, T. et al. Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol 91, 903–906 (2010). https://doi.org/10.1007/s12185-010-0586-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-010-0586-9

Keywords

Search

Navigation